Tesamorelin Before and After: What the Clinical Trials Actually Reported

The Phase 3 clinical trials that supported FDA approval documented a mean visceral adipose tissue (VAT) reduction of approximately 15.2% in the tesamorelin group versus a 5% increase in the placebo group over 26 weeks, measured by CT scan. The pooled analysis of both trials confirmed a 15 to 18% relative VAT reduction across 816 patients. In absolute terms, this represented a mean reduction of approximately 32.5 cm² in CT cross-sectional area at the L4-L5 vertebral level. At 52 weeks in the extension phase, patients who continued tesamorelin reached approximately 18% VAT reduction versus baseline. These are the controlled trial numbers. Individual variation is substantial, and the approved trial population was HIV-positive adults with lipodystrophy, not the general adult population seeking GH optimization.

CT-measurable VAT reduction begins diverging from placebo at approximately 12 weeks in the clinical trial data. Statistically significant differences in VAT are fully established at 26 weeks. IGF-1 elevation, which confirms GH axis response, is measurable within days to weeks. Triglyceride improvements track the VAT reduction and are measurable at similar timeframes. What is visible externally is a more nuanced question. Waist circumference decreased by approximately 2.1 cm on average in the trials over 26 weeks. This is a modest measurement change and may not be visibly apparent to a patient, particularly because tesamorelin reduces visceral fat while largely preserving subcutaneous fat and lean mass. Patients expecting a dramatic visual change in abdominal appearance within the first 4 to 8 weeks are working with expectations that exceed what the clinical trial timeline supports.

No. This is one of the most frequently misunderstood aspects of the tesamorelin before and after picture. In the Phase 3 trials, total body weight decreased by only approximately 1.2 to 1.8 kg on average over 26 weeks. This modest scale weight change occurs despite a meaningful 15% reduction in visceral fat because tesamorelin selectively targets visceral adipose tissue while largely preserving subcutaneous fat (which decreased only 0.8%, not statistically significant) and lean mass. GH’s anabolic effect on muscle tissue can partially offset fat mass reductions on the scale. The bathroom scale is the wrong measurement tool for assessing tesamorelin’s effect. CT-measured VAT, DEXA body composition, or waist circumference are more appropriate outcome measures for a clinical monitoring protocol.

The extension phase data from the original Phase 3 trials provides a clear answer. Patients who responded to tesamorelin at 26 weeks and were then switched to placebo for the 26-week extension phase showed reversion toward their baseline VAT within approximately 3 months of discontinuation. The visceral fat returned when treatment stopped. This does not represent a failure of the drug. It reflects the maintenance-dependent nature of GH axis support. Growth hormone’s metabolic effects require continued signaling to sustain. When the tesamorelin stimulus is removed, the body’s natural GH production pattern resumes, and the VAT reduction it had produced gradually reverses. This is consistent with how most hormonal interventions work and is something a licensed provider will discuss clearly as part of the protocol conversation before treatment begins.

The Phase 3 trials that supported FDA approval enrolled HIV-positive adults with antiretroviral therapy-associated lipodystrophy. There is no equivalent Phase 3 controlled trial in non-HIV adults published in the peer-reviewed literature. The mechanism of action, GHRH receptor stimulation and downstream GH and IGF-1 elevation, operates identically regardless of HIV status. The lipolytic effect of GH on visceral adipose tissue is not HIV-specific. However, the documented evidence for visceral fat reduction in the specific controlled trial setting applies to that trial population. Off-label use in adults without HIV-associated lipodystrophy who have excess visceral fat is legally permissible with a physician prescription, and some providers do discuss tesamorelin for this indication, but they are extrapolating from the mechanism and the approved population data rather than from an equivalent controlled trial in their specific patient population.

GH has opposing effects on glucose metabolism. It promotes lipolysis and can transiently reduce insulin sensitivity. The Phase 3 trials measured glucose parameters specifically because of this concern. The conclusion from the controlled data at 26 and 52 weeks was that there were no clinically meaningful differences in glucose parameters between tesamorelin and placebo in the trial populations. However, the FDA prescribing information notes that glucose intolerance and diabetes are possible adverse effects, and IGF-1 and glucose monitoring are standard parts of any protocol. Patients with pre-existing glucose abnormalities, insulin resistance, or elevated HbA1c warrant closer monitoring. A provider reviewing a patient’s baseline metabolic panel before prescribing tesamorelin will assess this specifically rather than applying a single approach to all patients.

The Phase 3 trials documented an approximately 81% increase in IGF-1 from baseline in the tesamorelin group, with IGF-1 levels rising to the upper end of or somewhat above the young-adult reference range in some patients. The FDA label includes monitoring guidance for IGF-1 because elevated IGF-1 is associated with certain adverse effects at supraphysiological levels. Active malignancy is a contraindication because IGF-1 is a mitogenic signal. The trials found no clinically significant increase in malignancy risk in the 816-patient study population, but the treatment duration was 52 weeks and the population was a specific medical population, not a general risk assessment. Standard clinical practice includes baseline IGF-1 documentation and monitoring during the protocol, with dose adjustment if levels exceed the upper reference range. The full monitoring framework is outlined in the companion article, What Labs Do You Need Before Starting Peptide Therapy.

GLP-1 receptor agonists such as semaglutide and tirzepatide produce weight loss across all fat compartments roughly proportional to how much fat is present. They are highly effective for total fat and weight reduction. Tesamorelin is selective for visceral fat without meaningful effects on subcutaneous fat or total body weight. For patients who have already achieved substantial weight loss on GLP-1 therapy but retain visceral fat disproportionate to their total body fat, tesamorelin’s selective visceral targeting addresses a gap that GLP-1 medications do not. For patients who have not yet pursued weight loss interventions and carry both visceral and subcutaneous excess fat, the clinical priorities and appropriate intervention sequence are a decision for a licensed provider based on the specific clinical picture. The two medication classes are not mutually exclusive and the decision between them, or the sequencing of them, requires individual clinical evaluation.